They mimic natural GLP-1 but last much longer in the body, providing more sustained effects on blood sugar control and appetite regulation
Many people may not have symptoms, and the liver can still work normally
This evidence, drawn from several major clinical trials, reveals that GLP-1 RAs like Semaglutide and Tirzepatide can significantly reduce the risk of cardiovascular events, chronic kidney disease, and liver disease while improving conditions like sleep apnea and osteoarthritis
Muraki K et al
Giao hng nhanh thch Hong c Huy mua ti rocy.vn c xp hng 5 5 sao Sn phm chnh hng, y tem mc
In Summary it led to : A1c Reduction up to 2% Weight loss reaching 29% Reduced Liver fat Drop blood pressure by 14 points decreased inflammatory markers reduced osteoarthritis flare ups To view or add a comment, sign in More Relevant Posts New in Med by Cell Press: In a 24-week, randomized, double-blind, placebo-controlled phase 2 trial in Chinese adults with obesity (BMI 30 kg/m2, no diabetes) once-weekly mazdutide 9 mg produced a mean 12.78% weight loss versus a 1.80% gain with placebo (treatment difference 14.58%